Page 1

For personal use only TELIX PHARMACEUTICALS Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401 , 55 Flemington Road North Melbourne Victoria , 3051 Australia ASX RELEASE Activities Report and Appendix 4C for September 2021 Quarter Melbourne ( Australia ) - 21 October 2021. Telix Pharmaceuticals Limited ( ASX : TLX , ' Telix ' , the ' Company ' ) today provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2021. All figures are in AUD unless otherwise stated . Financial Summary • Telix held cash reserves of $ 45.55 million on 30 September 2021 ( $ 49.62 million held on 30 June 2021 ) . • • Net operating outflows during the quarter were $ 7.59 million , with total operating outflows of $ 21.14 million in line with forecasts . $ 12.48 million was invested in R & D and clinical development activities during the quarter . Cash inflows during the quarter include $ 12.12 million Australian Government R & D tax refund , $ 1.16 million in receipts from customers , and $ 2.85 million in proceeds from the exercise of options from employees and directors . • Cash runway as per the attached Appendix 4C is 5.8 quarters of operations based on net cash used in operations in September 2021 quarter and exclusive of any anticipated revenue from sales of an approved product . Telix considers that the Company has four quarters of runway based on planned activity and capital management . • Cash runway remains sufficient to fund commercial launch of Illuccix® ( TLX591 - CDX ) and complete ZIRCON Phase III study.¹ Activities Report Activities during the September 2021 quarter were directed to final stages of preparation for launch of the Group's first commercial product , Illuccix ( TLX591 - CDx ) the investigational prostate cancer imaging kit for the preparation of 68Ga - PSMA - 11 injection , pending receipt of regulatory approvals . In parallel , the Company continues to advance its core pipeline of molecularly targeted radiation ( MTR ) late - stage clinical assets for both diagnostic and therapeutic use , in prostate , kidney and brain cancer and rare diseases ( bone marrow conditioning ) . Dr. Christian Behrenbruch , Managing Director and CEO of Telix said , " We have been intensely focused on preparations for the launch of our first commercial product Illuccix , while at the same time have continued to effectively advance the programs in our multi - asset core clinical pipeline . The inclusion of PSMA - PET2 imaging , including Ga - 68 PSMA - 11 , in the National Comprehensive Cancer Network ( NCCN ) GuidelinesⓇ for prostate cancer is an important validation that cements the acceptance of this new imaging modality and will drive clinical and payor adoption . The updated NCCN guidelines endorse the use of PSMA - PET for a broader patient population³ , significantly expanding the total addressable market for Illuccix . 1 Subject to approvals in the relevant jurisdictions . None of Telix's products have attained a marketing authorisation in any country . 2 Prostate specific membrane antigen ( PSMA ) positron emission tomography ( PET ) imaging 3 NCCNⓇ Prostate Cancer Guidelines Update , Version 1.2022 - 10/09/21 Page 1